Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289478 | 0.79 | HTR1B (0.59) | HTR1BALDH1A1KDM4ETDP1KCNA3 | |
| SCHEMBL442767 | 0.79 | HTR1B (0.54) | HTR1BALDH1A1KDM4ETDP1KCNA3 | |
| SCHEMBL29577853 | 0.79 | HTR1B (0.54) | HTR1BALDH1A1KDM4ETDP1KCNA3 | |
| Lithium SCHEMBL6571336 | 0.77 | HTR1B (0.52) | HTR1BALDH1A1KDM4ETDP1KCNA3 | |
| SCHEMBL7457103 | 0.77 | HTR1B (0.52) | HTR1BALDH1A1KDM4ETDP1KCNA3 | |
| Methane SCHEMBL10959030 | 0.77 | HTR1B (0.52) | HTR1BALDH1A1KDM4ETDP1KCNA3 | |
| SCHEMBL997311 | 0.75 | HTR1B (0.55) | HTR1BALDH1A1KDM4ETDP1KCNA3 | |
| SCHEMBL17449919 | 0.75 | HTR1B (0.50) | HTR1BALDH1A1KDM4ETDP1KCNA3 | |
| SCHEMBL3632375 | 0.75 | ALDH1A1 (0.52) | HTR1BALDH1A1KDM4ETDP1KCNA3 | |
| Ethylene SCHEMBL4726812 | 0.75 | HTR1B (0.50) | HTR1BALDH1A1KDM4ETDP1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100447126-C | Omega substituted naphthyloxy-amino alkane den-ivative used as anti-hyperglycaemia agent and its preparation therefor | COUNCIL SCIENT IND RES (IN) | 2008-12-31 | — | — | CN | claimed |
| CN-1894200-A | Omega-substituted naphthyloxy amino alkane derivatives as antihyperglycemic agents and preparation thereof | COUNCIL SCIENT IND RES (IN) | 2007-01-10 | — | — | CN | claimed |
| EP-1682484-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-26 | — | — | EP | claimed |
| US-7081465-B2 | Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-25 | — | — | US | claimed |
| WO-2005042465-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-05-12 | — | — | WO | claimed |
| US-20040192688-A1 | Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2004-09-30 | — | — | US | claimed |
| EP-1435352-A2 | 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines | Wyeth Holdings Corporation (US) | 2004-07-07 | — | — | EP | claimed |
| EP-0582789-B1 | Novel 7-(substituted)-8-(substituted)-9-(substituted glycyl)amido-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID CO (US) | 2001-10-04 | — | — | EP | claimed |
| EP-0582829-B1 | 9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines as antibiotic agents | AMERICAN CYANAMID CO (US) | 2001-09-12 | — | — | EP | claimed |
| EP-0582788-B1 | 7-(Substituted)-9- (substituted glycyl)-amido)-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID CO (US) | 1998-07-29 | — | — | EP | claimed |
| US-5466684-A | 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1995-11-14 | — | — | US | claimed |
| US-5457096-A | Antibiotic | AMERICAN CYANAMID COMPANY (US) | 1995-10-10 | — | — | US | claimed |
| US-5442059-A | Antibiotics for mammalian and veterninary diseases | AMERICAN CYANAMID COMPANY (US) | 1995-08-15 | — | — | US | claimed |
| US-5420272-A | 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1995-05-30 | — | — | US | claimed |
| US-5371076-A | ANTIBIOTICS | AMERICAN CYANAMID COMPANY (US) | 1994-12-06 | — | — | US | claimed |
| EP-0618190-A1 | 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-10-05 | — | — | EP | claimed |
| US-5328902-A | Antibiotics | AMERICAN CYANAMID CO. (US) | 1994-07-12 | — | — | US | claimed |
| EP-0582788-A1 | 7-(Substituted)-9- (substituted glycyl)-amido)-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-02-16 | — | — | EP | claimed |
| EP-0582789-A1 | Novel 7-(substituted)-8-(substituted)-9- (substituted glycyl)amido -6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-02-16 | — | — | EP | claimed |
| EP-0582829-A1 | 9-(substituted glycyl) amido - 6-demethyl-6-deoxytetracyclines as antibiotic agents | AMERICAN CYANAMID COMPANY (US) | 1994-02-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192688-A1 | Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | APOB, LIPC, FABP3 | HTR1B 247/4885ALDH1A1 717/4885KDM4E 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.